lancet semaglutide Beyond Weight Loss: How the 'Blockbuster' Drug Could Finally Break Alcohol Addiction On the cover, a new

doi: 10.1074/jbc.M408754200 68 SenA.ImlayJ

Weight loss trajectories and magnitudes differ between patients with obesity without diabetes (SURMOUNT trials) and those with type 2 diabetes (SURPASS trials), with the former typically showing greater percentage weight loss

Can moderate alcohol use still cause nutrient deficiencies

Advertisement Advertisement Inclusion of genomic profiling and risk factors recommended for treatment planning Large retrospective analysis may prompt prospective studies Robust signal from observational study raises prospect of a long-sought medical therapy Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors Study is first to show reduction in autoimmune disease with the common diabetes and obesity drugs Surgical intervention linked to increased lifespan and reduced complications

Glutathione IV Therapy restores these antioxidant levels and helps the skin achieve a balanced, healthy glow